BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Overview
USA - NASDAQ:BDTX - US09203E1055 - Common Stock
BDTX Key Statistics, Chart & Performance
The current stock price of BDTX is 3.82 USD. In the past month the price increased by 2.41%. In the past year, price increased by 32.18%.
BDTX Latest News, Press Relases and Analysis
BDTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
| ARGX | ARGENX SE - ADR | 89.07 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.96 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 9.34 | 21.93B |
Related stock screener links
About BDTX
Company Profile
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Company Info
BLACK DIAMOND THERAPEUTICS I
One Main Street, 14th Floor
Cambridge MASSACHUSETTS 02142 US
CEO: David M. Epstein
Employees: 24
Phone: 16174175868
BLACK DIAMOND THERAPEUTICS I / BDTX FAQ
Can you describe the business of BLACK DIAMOND THERAPEUTICS I?
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Can you provide the latest stock price for BLACK DIAMOND THERAPEUTICS I?
The current stock price of BDTX is 3.82 USD.
What is the dividend status of BLACK DIAMOND THERAPEUTICS I?
BDTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BDTX stock?
BDTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about BLACK DIAMOND THERAPEUTICS I (BDTX) stock?
13 analysts have analysed BDTX and the average price target is 10 USD. This implies a price increase of 161.68% is expected in the next year compared to the current price of 3.82.
Would investing in BLACK DIAMOND THERAPEUTICS I be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BDTX.
Can you provide the market cap for BLACK DIAMOND THERAPEUTICS I?
BLACK DIAMOND THERAPEUTICS I (BDTX) has a market capitalization of 217.51M USD. This makes BDTX a Micro Cap stock.
BDTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BDTX. When comparing the yearly performance of all stocks, BDTX is one of the better performing stocks in the market, outperforming 89.14% of all stocks.
BDTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BDTX. BDTX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
BDTX Financial Highlights
Over the last trailing twelve months BDTX reported a non-GAAP Earnings per Share(EPS) of 0.23. The EPS increased by 115.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.63% | ||
| ROA | 8.68% | ||
| ROE | 10.89% | ||
| Debt/Equity | 0 |
BDTX Forecast & Estimates
13 analysts have analysed BDTX and the average price target is 10 USD. This implies a price increase of 161.68% is expected in the next year compared to the current price of 3.82.